Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 7/20 | 0.65 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.64 |
| ▸ | ACE | P12821 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 3/20 | 0.61 |
| ▸ | MMP8 | P22894 | 3/20 | 0.61 |
| ▸ | MMP1 | P03956 | 2/20 | 0.61 |
| ▸ | MMP7 | P09237 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | IL1RN | P18510 | 1/20 | 0.57 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496933 | 1.00 | ECE1 (0.65) | ECE1ERAP2ACEMMP2MMP8 | |
| SCHEMBL17244052 | 1.00 | ECE1 (0.65) | ECE1ERAP2ACEMMP2MMP8 | |
| SCHEMBL29640357 | 1.00 | ECE1 (0.65) | ECE1ERAP2ACEMMP2MMP8 | |
| SCHEMBL30496932 | 1.00 | ECE1 (0.65) | ECE1ERAP2ACEMMP2MMP8 | |
| SCHEMBL15648656 | 0.93 | ECE1 (0.71) | ECE1ERAP2ACEIL1RNERAP1 | |
| SCHEMBL28478871 | 0.93 | ACE (0.64) | ECE1ACEMMP2MMP8MMP9 | |
| SCHEMBL15692405 | 0.93 | ECE1 (0.71) | ECE1ERAP2ACEIL1RNERAP1 | |
| SCHEMBL28518121 | 0.92 | MMP2 (0.59) | ECE1ERAP2MMP2MMP8MMP1 | |
| SCHEMBL28518120 | 0.92 | MMP2 (0.59) | ECE1ERAP2MMP2MMP8MMP1 | |
| SCHEMBL25264480 | 0.91 | MEN1 (0.64) | ACEPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116979-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | NISSAN CHEMICAL CORPORATION (JP) | 2024-04-11 | — | — | US | disclosed |
| US-20240067675-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | NISSAN CHEMICAL CORPORATION (JP) | 2024-02-29 | — | — | US | disclosed |
| EP-4265629-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | Nissan Chemical Corporation (JP) | 2023-10-25 | — | — | EP | disclosed |
| CN-116648455-A | Method for preparing lipid peptide | 日产化学株式会社 | 2023-08-25 | — | — | CN | disclosed |
| CN-116615435-A | Method for preparing lipid peptide | 日产化学株式会社 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022138957-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | 日産化学株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022138953-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | 日産化学株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067675-A1 | METHOD FOR PRODUCING LIPID PEPTIDE | VIP, NGLY1, NPPA | ECE1 2297/4885ERAP2 1163/4885ACE 604/4885 |
| US-20240116979-A1 | METHOD FOR PRODUCING LIPIDIC PEPTIDE | NPPA, VIP, NGLY1 | ECE1 1240/4885ERAP2 401/4885ACE 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.